The company expects the deal will help it launch an immunostaining technology, expand into US pharma services, and establish itself as a genetic testing leader in Japan.
Konica said that the deal represents its first step toward building a presence in the precision medicine field, with an eye toward Japan and then Europe.
Through prospective pancreatic ductal adenocarcinoma testing, researchers saw germline mutations in new genes and in cases outside of current germline testing criteria.
